Mirum Pharmaceuticals, Inc.
MIRM
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.1B
$99.83
▲ +1.52%
P/E
-6.86
Mkt Cap
$6.1B
52-Wk Range
$63.23–$130.00
52-Week Range
$63.23 - $130.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 33.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Focused pipeline targeting underserved rare liver disease markets with limited competition
- Oral drug formulations offering improved patient compliance versus existing alternatives
- Orphan drug designation providing regulatory advantages and market exclusivity periods
- Specialized expertise in cholestatic liver disease mechanisms and treatment development
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Strong growth ahead
Regulatory approvals and commercialization of LIVMARLI across multiple indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+8.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying MIRM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 5, 2026
Reported EPS of -$1.06 vs -$0.74 consensus (-42.8% surprise). Revenue of $176.2M vs $166.3M expected (+5.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-42.8%
Revenue trend · last 8Q
—
+43%
+61%
+64%
+47%
+50%
+43%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$90.4M
$99.4M
$111.6M
$127.8M
$133.0M
$148.9M
$159.9M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 27, 2026
vs Industry
How MIRM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related